Ghrelin, leptin and adiponectin levels in Gaucher disease type I patients on enzyme replacement therapy

• Published in: Clinical nutrition (Edinburgh, Scotland) Vol. 34; no. 4; pp. 727 - 731
• Main Authors: Doneda, Divair, Lopes, André L., Teixeira, Bruno C., Mittelstadt, Suzana D., Moulin, Cileide C., Schwartz, Ida V.D.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.08.2015
• Subjects: Adiponectin; Adiponectin - blood; Adult; biomarkers; Body Mass Index; Cholesterol, HDL - blood; Cholesterol, LDL - blood; Cross-Sectional Studies; Enzyme Replacement Therapy - methods; Female; Gastroenterology and Hepatology; Gaucher Disease - blood; Gaucher Disease - complications; Gaucher Disease - therapy; Gaucher disease type I; genetic disorders; Ghrelin; Ghrelin - blood; glucose; high density lipoprotein cholesterol; Humans; Insulin; Insulin Resistance; Leptin; Leptin - blood; low density lipoprotein cholesterol; Male; metabolic syndrome; Metabolic Syndrome - blood; Metabolic Syndrome - etiology; Middle Aged; Nutrition Assessment; Nutritional Status; overweight; Overweight - blood; Overweight - etiology; patients; therapeutics; triacylglycerols; Triglycerides - blood; waist circumference; Young Adult; HOMA-IR; T2DM; Gaucher disease type I; SRT; Ghrelin; Leptin; ERT; Insulin; GD; Adiponectin; BMI; enzyme replacement therapy; body mass index; Gaucher disease; type 2 diabetes mellitus; substrate reduction therapy; homeostatic model assessment of insulin resistance
• ISSN: 0261-5614; 1532-1983; 1532-1983
• DOI: 10.1016/j.clnu.2014.08.010

Gaucher disease type I (GD type I) is characterized by clinical heterogeneity and is associated with metabolic abnormalities such as increased basal metabolic rate. To evaluate ghrelin, leptin and adiponectin levels in patients with GD type I on enzyme replacement therapy (ERT). A cross-sectional study of patients with GD type I (n = 15), matched for sex, age and BMI with healthy controls. The levels of glucose, insulin, ghrelin, leptin and adiponectin were assessed in both groups. Insulin resistance was defined by the index HOMA-IR. Eight patients had adequate weight, seven were overweight (4 preobese, 3 obese class I). Eight patients presented metabolic syndrome, five of whom with insulin resistance. The median levels of ghrelin, leptin and adiponectin of the patients did not differ from those of the controls. Ghrelin and adiponectin levels were correlated with each other; inversely correlated with BMI, waist circumference and triglyceride levels; and directly correlated with HDL-cholesterol. Leptin levels were inversely correlated with LDL-cholesterol and directly correlated with BMI, waist circumference, enzyme dosage, triglycerides, insulin, and HOMA-IR. Metabolic syndrome and overweight appear to be common in patients with GD type I on ERT. As leptin was strongly associated with insulin and HOMA index, it could become a biomarker to assess early evidence of insulin resistance in patients with GD. Further studies are needed to investigate the associations found.